Novartis

Novartis AG (NYSE: NVS) is a world leader in offering medicines to protect health, cure disease and improve well-being. Our goal is to discover, develop and successfully market innovative products to treat patients, ease suffering and enhance the quality of life. We are strengthening our medicine-based portfolio, which is focused on strategic growth platforms in innovation-driven pharmaceuticals, high-quality and low-cost generics, human vaccines and leading self-medication OTC brands. Novartis is the only company with leadership positions in these areas. In 2006, the Group’s businesses achieved net sales of USD 37.0 billion and net income of USD 7.2 billion. Approximately USD 5.4 billion was invested in R&D. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 100,000 associates and operate in over 140 countries around the world.

About the Account

In October 2007, Ruder Finn Asia managed media relations for the opening of Novartis’ new pharmaceutical production center located at Tuas Biomedical Park, a state-of-the art facility that supports the company’s long-term growth in Asia. This facility in Singapore is one of the largest investments Novartis has executed for a manufacturing plant in Asia - investing approximately US$180 million to construct the plant. Excellent media coverage was achieved including Bloomberg, Reuters and The International Herald Tribune.

http://www.novartis.com